Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Werewolf TherapeuticsHOWL -4.02%32 Cash Ratio is 2.80 as of Jun. 2026, which is 63% below its 10-year median of 7.60. GuruFocus rates HOWL with a GF Score™ of 32/100 and a GF Value™ of $3.78 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,379 Biotechnology companies, Werewolf Therapeutics ranks worse than 51.27% on this metric.
Werewolf Therapeutics has a Cash Ratio of 2.80. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Werewolf Therapeutics's Cash Ratio or its related term are showing as below:
HOWL'
s Cash Ratio Range Over the Past 10 Years
Min: 1.21 Med: 7.6 Max: 24.86
Current: 2.8
During the past 7 years, Werewolf Therapeutics's highest Cash Ratio was 24.86. The lowest was 1.21. And the median was 7.60.
HOWL's Cash Ratio is ranked worse than 51.27% of 1379
companies
in the Biotechnology industry
Industry Median: 2.93
vs HOWL: 2.80
Werewolf Therapeutics (NAS:HOWL) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Werewolf Therapeutics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Werewolf Therapeutics Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Werewolf Therapeutics's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Werewolf Therapeutics's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Werewolf Therapeutics (HOWL) has a Cash Ratio of 2.80 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Werewolf Therapeutics and its competitors. This is 63% below median its historical median of 7.60. Over the past decade, Werewolf Therapeutics' Cash Ratio has ranged from 1.21 to 24.86. According to the industry distribution chart, Werewolf Therapeutics ranks #707 out of 1379 companies in the Biotechnology industry, placing it in the top 51.3%.
Is Werewolf Therapeutics' Cash Ratio too high?
Werewolf Therapeutics' current Cash Ratio of 2.80 is 63% below median its 10-year median of 7.60. Over the past 10 years, this metric has ranged from a low of 1.21 to a high of 24.86. The Biotechnology industry median Cash Ratio is 2.93. Werewolf Therapeutics' value of 2.80 is 4.4% below this industry median. Based on the distribution chart, Werewolf Therapeutics ranks #707 out of 1379 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Werewolf Therapeutics has a GF Score™ of 32/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Werewolf Therapeutics' Cash Ratio compare to CVM and MRKR?
According to the Biotechnology industry distribution chart, Werewolf Therapeutics ranks #707 out of 1379 companies for Cash Ratio. This places Werewolf Therapeutics in the lower half of its industry. The industry median Cash Ratio is 2.93. Werewolf Therapeutics' value of 2.80 is 4.4% below this benchmark. Historically, Werewolf Therapeutics' own Cash Ratio has ranged from 1.21 to 24.86 over the past decade. While the company's 10-year median is 7.60 vs. the industry median of 2.93, Werewolf Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.93, based on 1,379 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Werewolf Therapeutics's current Cash Ratio of 2.80 is 4.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Werewolf Therapeutics and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Werewolf Therapeutics's current Cash Ratio is 2.80, which is 63% below median its own 10-year median of 7.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Werewolf Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Werewolf Therapeutics (HOWL) is currently considered Possible Value Trap. The stock's GF Value™ is $3.78, compared to a current price of $0.38 — trading 89.9% below its estimated fair value. The current Cash Ratio is 2.80, which is 63% below median its 10-year median of 7.60 and 4.4% below the Biotechnology industry median of 2.93. Werewolf Therapeutics' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Werewolf Therapeutics (HOWL), the current Cash Ratio is 2.80 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Werewolf Therapeutics (HOWL) Overvalued in 2026?
Based on GuruFocus' analysis, Werewolf Therapeutics stock appears to be undervalued.
The current stock price of $0.38 is trading 89.9% below its estimated GF Value™ of $3.78.
GuruFocus considers Werewolf Therapeutics to be Possible Value Trap.
Key valuation signals for HOWL:
Cash Ratio: 2.80 (63% below median its 10-year median of 7.60)
GF Value™: $3.78 vs. price of $0.38 (89.9% below fair value)
Industry Position: 4.4% below the Biotechnology median (#707 of 1379)
No single metric tells the full story. See the HOWL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.
32GF Score
Get the complete analysis for HOWL
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HOWL has been successfully added to your 
